Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vanda Pharmaceuticals Inc Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint


Thursday, 31 Jan 2013 06:55am EST 

Vanda Pharmaceuticals Inc announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD. The clinical study did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale (HAMD-17) after eight weeks of treatment as compared to placebo. Both tasimelteon and placebo treated patients had an approximately 40% reduction of their MDD symptoms from baseline. Tasimelteon was shown to be safe and well-tolerated, consistent with observations in prior studies. Given these current proof of concept clinical study results, Vanda has decided to discontinue all activities in this indication. 

Company Quote

10.59
0.03 +0.28%
21 Oct 2014